Global healthcare systems today are facing big challenges. Providers are overwhelmed and costs are growing at an unsustainable rate. Fortunately, the MEMS, sensors, and biochemistry industries are teaming up to develop solutions that can change the way we deliver care, improving healthcare delivery and outcomes. Microneedles are now a $5.4 billion market, dominated by applications in cancer therapy, vaccines, drug delivery, and aesthetics. MEMS has emerged as a cornerstone technology, propelling the evolution of microneedles toward unprecedented precision and efficacy in the realm of transdermal drug delivery and biosensing. These tiny structures represent a convergence of precision engineering and biomedical innovation that has already begun to contribute significant advances in healthcare by providing precise and minimally invasive solutions for a myriad of applications.
Many advancements in MEMS technology have propelled microneedles to be considered for new and exciting applications from administering vaccines to skin cancer treatments, wound healing, and even the treatment of mild dementia in Alzheimer’s patients. The proliferation of microneedle variants—solid, hollow, coated, dissolvable, and hydrogel-forming—underscores the versatility and adaptability of this technology. In this session, we will explore the latest advancements in MEMS-based microneedle technology, including the various materials and manufacturing methods currently being employed, early commercial success stories, and how this technology will impact healthcare delivery and biosensing in the future. This session will also guide attendees on how to prepare your company to compete in the biosensor and microneedle markets.
